The present results support GHSR as a therapeutic target that will implement the myogenic gene expression program in BAT, which has been proposed as a therapeutic strategy for obesity and obesity-related metabolic disorders like type 2 diabetes53. This evidence concerns the gene GHSR and obesity due to melanocortin 4 receptor deficiency.